ALKS 3831

Citigroups' Jonathan Eckard, Ph.D. continues to believe that Alkermes Plc (NASDAQ: ALKS) is a top name among biotech stocks and remains on the Citi U.S. Focus List. On Wednesday, Eckard increased his price target on Buy-rated Alkermes to $85 from a previous $72, reflecting the belief that...